ADPT · Healthcare
Adaptive Biotechnologies Corp
31/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
company insiders are selling
Hedge funds
57
Congress
No data
Insiders
0
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$4.0B
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers…
Who's behind the signal
Every informed buyer we can see on ADPT, across all three feeds.
Hedge funds · 10
Tudor Investment (Paul Tudor Jones)
Increased +42%
Point72 (Steve Cohen)
Increased +403%
D.E. Shaw & Co
Increased +3%
Millennium Management (Englander)
Increased +5791%
Citadel Advisors
Increased +538%
AQR Capital Management
Increased +4%
+4 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
Company insiders
Selling
Recent sells85
Not a model pick — but on our radar.
ADAPTIVE BIOTECHNOLOGIES CORP isn't in the top-10 model right now, but 10 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
10
Investors
0
New positions
6
Increasing
3
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.1%
Position change
+42%
0.1% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+403%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+3%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+5791%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+538%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+4%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.5×
% of portfolio
1.2%
Position change
—
1.2% of Viking Global Investors's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
−2%
0.2% of ARK Invest's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−66%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−36%
0.0% of Gotham Asset Mgmt's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ADAPTIVE BIOTECHNOLOGIES CORP
No insider trades found in the last 90 days
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ADAPTIVE BIOTECHNOLOGIES CORP or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订